Navigation Links
Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
Date:10/13/2008

CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc. (http://www.neuronascent.com) announced today that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer's disease, depression and ischemia. Neuronascent has received grants and funding from Maryland Department of Business and Economic Development Challenge Investment Program; Maryland Industrial Partnerships in collaboration with University of Maryland, Baltimore; and Jefferson Corner Group I, LLC, a member-managed angel fund located in Charlottesville, Virginia designed to capitalize on the growth in entrepreneurial activity in Charlottesville and other areas. This is the Company's second award from the Challenge Investment Program.

The company's lead compounds, currently in preclinical testing, aim to replace damaged neurons, restore neurons critical to cognition and memory and enhance neuroprotection against neurodegenerative diseases. Results from recent animal studies show a reversal of cognitive loss in aged mice to young levels.

"Our lead compound for Alzheimer's disease may represent the first disease-modifying therapeutic under development," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer. Dr. Kelleher-Andersson went on to say, "This funding affords us the opportunity to pursue multiple preclinical studies to further develop our lead agents for clinical trials."

Founded in 2004 by Dr. Kelleher-Andersson, Neuronascent, Inc. is a small-molecule central nervous system drug discovery company developing novel therapeutics based on the science of neurogenesis that target Alzheimer's disease, depression and ischemia. Neuronascent has laboratories in Rockville and Walkersville, Maryland.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe har
'/>"/>

SOURCE Neuronascent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
3. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Theranostics Health Receives Green Light to Perform Clinical Testing
8. StemCor Systems Receives CE Mark for MarrowMiner(TM) System for Bone Marrow Collection
9. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Unique Hearing Aid Receives Patent Protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation ... conference call on Tuesday, August 5, 2014, at 8:30 ... second quarter 2014 financial results. An audio ... through the Investor Relations portion of the CVS Caremark ... visit http://info.cvscaremark.com/investors . This webcast will be archived ...
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2
... DALLAS, September 6, 2011 The " Global ... " analyzes the global fetal and neonatal care equipment market by ... trends for the fetal and neonatal care market across 18 countries ... World. Explore market data tables and in-depth ...
... 6, 2011 The Dutch biotech company ... company Clavis Pharma ASA (Clavis) disclosed signing a research ... biomarkers for selection of individual Acute Myeloid Leukemia (AML) ... in development at Clavis. This drug, elacytarabine, is a ...
Cached Medicine Technology:MarketsandMarkets: Global Fetal and Neonatal Care Equipment Market Forecast (2011-2016) 2MarketsandMarkets: Global Fetal and Neonatal Care Equipment Market Forecast (2011-2016) 3MarketsandMarkets: Global Fetal and Neonatal Care Equipment Market Forecast (2011-2016) 4Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine 2
(Date:7/27/2014)... the leader in compression technology and sports medicine, has expanded ... The wrist support features an adjustable velcro strap and provides ... more commonly referred to as tennis elbow and golfers elbow, ... tendons attached to the outside of the elbow. Although this ... the wrist and fingers turn into a tendon that attaches ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... of hepatitis E virus (HEV) transmission by blood components ... have HEV in their plasma. The findings, published in ... blood components (eg, red cells, platelets, and fresh frozen ... England. , The study retrospectively screened 225 000 ... Oct, 2012 and Sept, 2013 for HEV RNA. 79 ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... (GFRP) Composites Market By Raw Material, By Manufacturing ... & Others) & By Geography – Global Trends ... global GFRP Composites market with an analysis and ... market data tables and 107 figures spread through ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2
... Valentine,s Day is a,time to celebrate healthy relationships ... Foundation,s (AACDCF) Give Back A Smile,(GBAS) program celebrates that ... given their time and expertise pro bono to help,restore ... To date,more than 600 GBAS cases have been completed ...
... Prescription Needed to Keep Community Pharmacy Healthy", ... today signed into law the more than $150 ... by Congress. In response,Bruce Roberts, RPh, executive vice ... (NCPA) issued the following statement:, "This is ...
... by the,Centers for Disease Control and Prevention (CDC) report ... autism. In Georgia, these statistics,are one in 131. Autism ... alarming speed. It is estimated that more than 10,000,children ... a disorder of,unknown origin that has no known cure. ...
... cancer cells grow and how they can be killed ... potential to develop into fully mature or differentiated cells and ... the cause of the most common form of childhood cancer, ... aggressive treatment for the disease and could result in the ...
... Council on,Disability (NCD) will release its latest report titled, ... Success and Proposed,Policy Solutions, at a news conference at ... Health and Human Services, 200 Independence Avenue,SW, Room 505A, ... and the,media and free of charge., The goal ...
... Multi-Specialty Group Automates and Connects Physicians, ... ... 13 ,Allscripts, the leading provider of clinical software, connectivity ... that Mankato Clinic has selected the Allscripts Electronic Health,Record ...
Cached Medicine News:Health News:Caring Give Back A Smile Volunteer Dental Professionals Donate Over $5 Million in Services to Survivors of Domestic Violence 2Health News:2008 Georgia Walk for Autism Supporters Gather in Atlanta for Kick-Off Dinner 2Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 2Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 3Health News:National Council on Disability to Make Recommendations on Youth with Disabilities in the Foster Care System 2Health News:Mankato Clinic Selects Allscripts Electronic Health Record 2Health News:Mankato Clinic Selects Allscripts Electronic Health Record 3Health News:Mankato Clinic Selects Allscripts Electronic Health Record 4
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... the age of 3 can choose either the ... same design principle applies to both:, ,Maximize ... aerosol output when the patient exhales using two ... to leave the nebulizer. The result is a ...
... been developing diverse medical products ... Our medical-surgical products have earned ... quality and customer satisfaction. Graham-Fields ... Labtron® line of diagnostic instruments, ...
... medication as well as humidification, try Flo-Mist™., ... high volume, continuous medication nebulizer (CMN), engineered ... Its 200 ml reservoir and jet flow ... of nebulized medication delivery at 25 ml/hr. ...
Medicine Products: